Movers and Shakers - Richard Wallace

Richard J Wallace has joined the Bridgehead Board as a Non-Executive Director, following 15 years at GlaxoSmithKline (GSK), where he was most recently Senior Vice President of Global Product Strategy, accountable for Global Health Outcomes, Scientific Communications, Global Commercial Strategy and Business & Commercial Analysis. He also served as a member of its Research and Development Executive, Commercial Operations Committee, Product Management Board and Scientific Advisory Board. During his years at GSK and it's heritage companies, Richard held positions from Vice President Commercial (Canadian Pharmaceuticals), Vice President U.S. Business Development, Vice President Sales & Marketing (U.S. Oncology and HIV), Vice President Clinical Development and Product Strategy, and Vice President of Global Commercial Strategy. His experience prior to joining GSK included eight years with Bristol-Myers Squibb and seven years at Johnson & Johnson in assignments from Marketing, Sales, Manufacturing and General Management. Richard received BCom and BCom(Hons) degrees from Rhodes University, South Africa and currently serves on the board of directors of Avigen Inc, ImmunoGen Inc and Clinical Data Inc. Bridgehead International CEO, Timothy Fitzgerald commented: “We are delighted at Richard’s decision to join the team at a time when we are pushing ahead with a major expansion of our activities in North America. His senior level experience, particularly in the market access and health outcomes fields will be of real value to Bridgehead and its clients.” Over the past four years Bridgehead’s Market Access business has grown to be the single largest practice area in the company. Whilst much of Bridgehead’s work on pricing, reimbursement and market access is global in nature (US, top five in Europe and Japan), the company is increasingly being asked to use its knowledge and experience to address US-specific issues through: • Payer research • Therapy area scanning • Pricing strategy for commercialisation • Reimbursement negotiation strategy • Product life cycle pricing strategy • Pharmacoeconomic assessments • Health technology assessment support